Every material Form 8-K National Health Investors filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On December 15, 2025, National Health Investors entered into updated change-in-control severance agreements with five named executive officers, replacing agreements dated February 26, 2024. The agreements set cash severance multiples, COBRA coverage and equity vesting if an executive is terminated without cause or resigns for good reason within two years after a change in control.
Agreements dated December 15, 2025 cover D. Eric Mendelsohn, Kristin S. Gaines, Kevin C. Pascoe, John L. Spaid and David L. Travis
Lump sum severance multiples are 3.0 times for Mendelsohn, 2.0 times for Pascoe and Spaid, and 1.5 times for Gaines and Travis
Benefits include 18 months of COBRA coverage and accelerated vesting of time-based equity awards
Two National Health Investors board members, Robert G. Adams and Charlotte A. Swafford, notified the board on November 5, 2025, that they will leave the board in 2026. Both said their decisions were not due to any disagreement with the company on operations, policies or practices.
Robert G. Adams will not stand for reelection; his term ends at the 2026 annual meeting of stockholders.
Charlotte A. Swafford will retire from the board effective May 27, 2026, immediately before the 2026 Annual Meeting.
The filing states neither departure stemmed from a disagreement with the company.
National Health Investors reported third-quarter 2025 results on November 6, 2025, with diluted net income per share attributable to common stockholders of $0.69, up from $0.65 a year earlier, and total revenues of $89.8 million, up from $82.9 million. The company raised its full-year 2025 guidance, with Normalized FFO per diluted share now expected at $4.88 to $4.91, up from $4.78 to $4.82, and said this was the third guidance increase this year.
Q3 2025 diluted EPS was $0.69 versus $0.65 in Q3 2024; nine-month diluted EPS was $2.22 versus $2.17.
Q3 2025 Normalized FFO per diluted share was $1.32 versus $1.03; NAREIT FFO per diluted share was $1.09 versus $1.03.
Q3 results include $12.1 million in write-offs of straight-line rents receivable tied to early lease terminations.
2025 guidance: NAREIT FFO per diluted share raised to $4.62 to $4.65 from $4.46 to $4.50; Normalized FFO per diluted share raised to $4.88 to $4.91 from $4.78 to $4.82.
National Health Investors completed an underwritten public offering of $350 million of 5.350% senior notes due February 1, 2033, on September 26, 2025. The notes add to the company's debt obligations, and the indenture includes limits on additional borrowing and a requirement to maintain a pool of unencumbered assets.
Offering size: $350 million aggregate principal amount of 5.350% Senior Notes due 2033, sold at 98.903% of principal
Interest is payable semi-annually on February 1 and August 1, starting February 1, 2026
Underwriters: J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC, under an agreement dated September 22, 2025
Indenture covenants limit additional indebtedness and require maintaining a pool of unencumbered assets
National Health Investors reported second-quarter 2025 results with diluted EPS of $0.79, down from $0.81 a year earlier, while normalized FFO per diluted share rose to $1.22 from $1.18. The company lowered its 2025 NAREIT FFO per diluted share guidance to $4.46-$4.50 from $4.64-$4.70 but raised its normalized FFO and normalized FAD guidance, and it expects an $8.8 million reduction in third-quarter rental income tied to the Discovery lease termination.
Diluted EPS was $0.79 versus $0.81 in the prior-year quarter, including $1.3 million of proxy contest expenses.
Normalized FFO per diluted share was $1.22 versus $1.18; NAREIT FFO per diluted share was $1.19 versus $1.18.
2025 NAREIT FFO per diluted share guidance was lowered to $4.46-$4.50 from $4.64-$4.70; normalized FFO guidance was raised to $4.78-$4.82 from $4.68-$4.73.
Discovery Senior Living lease was terminated effective August 1, 2025, with an expected $8.8 million third-quarter rental income reduction.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every National Health Investors filing is on SEC EDGAR ↗. 8-K briefs of other companies →